It has been revealed that two arthritis drugs reduce the risk of death and the need for ventilators among hospitalised COVID-19 patients. Drugs tocilizumab and sarilumab were analyse in nearly 11,000 patients, with the results published in the Journal of the American Medical Association. The World Health Organisation (WHO) was prompted by the new study to recommend the use of the medicines known as IL-6 inhibitors among patients with severe or critical COVID-19.
Among hospitalised patients, administering one of the drugs in addition to corticosteroids reduced death risk by 17%, compared to the use of the corticosteroids alone. For those not on ventilators, the risk of progressing to mechanical ventilation or mortality was reduced to 21%. The drugs are normally used to treat rheumatoid arthritis.
#MaltaDaily
Photo Source: Conseil de l’Europe